Low plasma adiponectin levels predict progression of coronary artery calcification

DM Maahs, LG Ogden, GL Kinney, P Wadwa… - Circulation, 2005 - Am Heart Assoc
DM Maahs, LG Ogden, GL Kinney, P Wadwa, JK Snell-Bergeon, D Dabelea, JE Hokanson
Circulation, 2005Am Heart Assoc
Background—Circulating adiponectin levels are lower in men than in women and lower in
advanced coronary artery disease, obesity, and type 2 but not type 1 diabetes. However, it is
not known whether low adiponectin levels predict development of atherosclerosis
independently of other cardiovascular risk factors. Methods and Results—Progression of
coronary artery calcification (CAC) over an average of 2.6 years (range, 1.6 to 3.3) was
assessed in a cohort of patients with type 1 diabetes and nondiabetic subjects 19 to 59 …
Background— Circulating adiponectin levels are lower in men than in women and lower in advanced coronary artery disease, obesity, and type 2 but not type 1 diabetes. However, it is not known whether low adiponectin levels predict development of atherosclerosis independently of other cardiovascular risk factors.
Methods and Results— Progression of coronary artery calcification (CAC) over an average of 2.6 years (range, 1.6 to 3.3) was assessed in a cohort of patients with type 1 diabetes and nondiabetic subjects 19 to 59 years of age. In this nested case-control substudy, plasma adiponectin levels were measured in 101 cases with significant CAC progression and in 205 controls. Controls were oversampled on the basis of age, gender, diabetes status, and presence of baseline CAC. In conditional logistic regression adjusted for baseline CAC volume and other significant predictors of CAC progression, adiponectin levels were inversely related to progression of CAC in diabetic (OR, 0.47; 95% CI, 0.24 to 0.94) and nondiabetic (OR, 0.15; 95% CI, 0.05 to 0.40 for a doubling in adiponectin levels) subjects. Adjustment for additional cardiovascular risk factors did not change this association. In conditional logistic regression models by quartiles of plasma adiponectin levels, the probability value for trend was statistically significant for all participants (P<0.001) and nondiabetic participants (P<0.001) and was borderline for type 1 diabetics (P=0.08).
Conclusions— Low plasma adiponectin levels are associated with progression of CAC in type 1 diabetic and nondiabetic subjects independently of other cardiovascular risk factors.
Am Heart Assoc